Genvec (GNVC) 10-Q 10 May 17 2017 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2017	Apr. 30, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	GENVEC INC
Entity Central Index Key	934,473
Trading Symbol	gnvc
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		2,273,632
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 2,536	$ 3,667
Investments, at fair value	1,749	3,498
Accounts receivable, net	84	22
Prepaid expenses and other	224	271
Total current assets	4,593	7,458
Property and equipment, net	255	191
Other assets	58	58
Total assets	4,906	7,707
Current liabilities:
Accounts payable	1,635	957
Accrued expenses and other	560	890
Total current liabilities	2,195	1,847
Warrant liabilities, at fair value	2,034	1,059
Other liabilities	94	96
Total liabilities	4,323	3,002
Stockholders' equity:
Preferred stock, $0.001 par value, 5,000 shares authorized; none issued and outstanding at March 31, 2017 or December 31, 2016
Common stock, $0.001 par value; 55,000 shares authorized; 2,274 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively	2	2
Additional paid-in capital	295,482	295,333
Accumulated other comprehensive loss	(1)	(3)
Accumulated deficit	(294,900)	(290,627)
Total stockholders' equity	583	4,705
Total liabilities and stockholders' equity	$ 4,906	$ 7,707

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parentheticals) - $ / shares shares in Thousands	Mar. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	55,000	55,000
Common stock, shares issued	2,274	2,274
Common stock, shares outstanding	2,274	2,274

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Revenues	$ 114	$ 290
Operating expenses:
General and administrative	2,654	1,412
Research and development	767	737
Total operating expenses	3,421	2,149
Operating loss	(3,307)	(1,859)
Other income/(expense):
Change in fair value of warrant liabilities	(975)
Interest and other income/(expense), net	9	(1)
Total other expense, net	(966)	(1)
Net loss	$ (4,273)	$ (1,860)
Basic and diluted net loss per share (in dollars per share)	$ (1.88)	$ (1.08)
Shares used in computation of basic and diluted net loss per share (in shares)	2,274	1,726
Comprehensive Loss:
Net loss	$ (4,273)	$ (1,860)
Unrealized holding gain on securities available for sale	2	5
Comprehensive loss	$ (4,271)	$ (1,855)

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net loss	$ (4,273)	$ (1,860)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	23	26
Non-cash charges for stock-based compensation	149	202
Non-cash consideration for release of security interest		4
Change in fair value of warrant liabilities	975
Changes in current assets and liabilities, net	331	(138)
Changes in non-current assets and liabilities, net	(2)	(3)
Net cash used in operating activities	(2,797)	(1,769)
Cash flows from investing activities:
Purchases of property and equipment	(87)
Proceeds from sale of property and equipment	1
Proceeds from maturities of investment securities	1,752	1,087
Net cash provided by investing activities	1,666	1,087
Change in cash and cash equivalents	(1,131)	(682)
Beginning balance of cash and cash equivalents	3,667	7,015
Ending balance of cash and cash equivalents	$ 2,536	$ 6,333

General

General	3 Months Ended
	Mar. 31, 2017
General Disclosure [Abstract]
General	(1) General Basis of Presentation The (a) condensed balance sheet as of December 31, 2016, which has been derived from audited financial statements, and (b) unaudited interim condensed financial statements included herein have been prepared by GenVec, Inc. (“GenVec”, “we”, “our”, “us”, or the “Company”) without audit pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. We believe the disclosures are adequate to make the information presented not misleading. The condensed financial statements included herein should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to present fairly the financial position of the Company as of March 31, 2017 and December 31, 2016 and the results of its operations and cash flows for the three-month periods ended March 31, 2017 and March 31, 2016. The results of operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year. Business GenVec is a clinical-stage biopharmaceutical company with an entrepreneurial focus on leveraging its proprietary AdenoVerse™ gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. We are pioneers in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. Our lead product candidate, CGF166, is licensed to Novartis Institutes for BioMedical Research, Inc. (together with Novartis AG and its subsidiary corporations, including Novartis Pharma AG, “Novartis”) and is currently in a Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. In addition to our internal and partnered pipeline, we also focus on opportunities to license our proprietary technology platform, including vectors and production cell lines, to potential collaborators in the biopharmaceutical industry for the development and manufacture of therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. We are working with prominent companies and organizations such as Novartis, Merial (a unit of Boehringer Ingelheim), Washington University in St. Louis, and the U.S. government, as well as promising young companies such as TheraBiologics, to support a portfolio of programs that addresses the prevention and treatment of a number of significant human and animal health concerns. Our combination of internal and partnered development programs address therapeutic areas such as hearing loss and balance disorders, oncology, bleeding disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (“RSV”), herpes simplex virus (“HSV”), malaria, and in the area of animal health, vaccines against foot-and-mouth disease (“FMD”). Our AdenoVerse gene delivery technology has the important advantage of localizing protein delivery in the body. This is accomplished by using our adenovector platform to locally deliver genes to cells, which then direct production of the desired protein. This approach reduces side effects typically associated with systemic delivery of proteins. For therapeutics, the goal is for the protein produced to have a meaningful effect in treating the cause, manifestation, or progression of the disease. For vaccines, the goal is to induce an immune response against a target protein or antigen. This is accomplished by using an adenovector to deliver a gene that causes production of an antigen, which then stimulates the desired immune reaction by the body. Our research and development activities yield product candidates that utilize our technology platform and represent potential commercial opportunities. For example, preclinical research in hearing loss and balance disorders indicates that the delivery of the atonal gene using our adenovector technology may have the potential to restore hearing and balance function. We are currently working with Novartis on the development of novel treatments for hearing loss and balance disorders that emerged from these research and development efforts. There are currently no effective therapeutic treatments available for patients who have lost all balance function, and hearing loss remains a major unmet medical problem. We have multiple vaccine candidates that leverage our core adenovector technology, including our vaccine candidates for the prevention or treatment of RSV and HSV. We also have a program to develop a vaccine for malaria, a program in which we are currently working in collaboration with the Laboratory of Malaria Immunology and Vaccinology (“LMIV”) of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (“NIAID”). Our business strategy is focused on entering into collaborative arrangements with third parties to complete the development and commercialization of our product candidates. In the event that third parties take over the development for one or more of our product candidates, the estimated completion date would largely be under the control of that third party rather than us. We cannot forecast with any degree of certainty which proprietary products or indications, if any, will be subject to future collaborative arrangements, in whole or in part, or how such arrangements would affect our development plan or capital requirements. Our programs may also benefit from subsidies, grants, or government or agency-sponsored studies that could reduce our development costs. An element of our business strategy is to pursue, as resources permit, the research and development of a range of product candidates for a variety of indications. This is intended to allow us to diversify the risks associated with our research and development expenditures. To the extent we are unable to maintain a broad range of product candidates, our dependence on the success of one or a few product candidates would increase. PLAN OF MERGER On January 24, 2017, the Company, Intrexon Corporation, a Virginia corporation (“Intrexon”), and Intrexon GV Holding, Inc., a Delaware corporation and wholly owned subsidiary of Intrexon (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, and on the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into GenVec (the “Merger”). GenVec will survive the Merger as a wholly owned subsidiary of Intrexon. For more information on the Merger, the Merger Agreement and its terms and conditions, see Note 11, “Subsequent Events,” . Except where it is clear from the context, the discussion in this Form 10-Q does not contemplate the consummation of the Merger or the integration of GenVec with Intrexon. GOING CONCERN As a result of the uncertainties involved in our business, we are unable to estimate the duration and completion costs of our research and development projects or when, if ever, and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete our research and development projects in a timely manner or our failure to enter into collaborative agreements, when appropriate, could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time to time in order to continue with our business strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business. Our estimated future capital requirements are uncertain and could change materially as a result of many factors, including the progress of our research, development, clinical, manufacturing, and commercialization activities. Management has determined the Company has suffered recurring losses from operations and has an accumulated deficit that raises substantial doubt about our ability to continue as a going concern for the next twelve months. The report of our independent registered public accounting firm for the year ended December 31, 2016 included an explanatory paragraph that expressed substantial doubt about our ability to continue as a going concern. Our financial statements do not include any adjustments that might result from the outcome of the uncertainty. If the merger with Intrexon is not consummated, our ability to continue as a going concern may depend on our ability to raise additional capital, attain further operating efficiencies, reduce expenditures, and, ultimately, to generate revenue. There are no assurances that these future funding and operating efforts will be successful. If management is unsuccessful in these efforts, our current capital is not expected to be sufficient to fund our operations for the next twelve months. Our financial statements as of March 31, 2017 do not include any adjustments that might result from the outcome of this uncertainty. Use of Estimates The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, and revenues and expenses during the period. Critical accounting estimates involved in applying our accounting policies are those that require management to make assumptions about matters that are highly uncertain at the time the accounting estimate is made and those for which different estimates reasonably could have been used for the current period. Critical accounting estimates are also those which are reasonably likely to change from period to period, and would have a material impact on the presentation of our financial condition, changes in financial condition, or results of operations. Our most critical accounting estimates relate to accounting policies for strategic collaborations and research contract revenues, research and development activities, stock-based compensation, and warrant liabilities. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances. Actual results could differ from these estimates. Fair Value of Financial Instruments The carrying amounts reported in the accompanying financial statements for cash, cash equivalents, investments, and warrant liabilities, approximate fair value of these financial instruments. The fair value for marketable securities and warrant liabilities is discussed in Notes 2 and 4, respectively. Revenue Recognition Revenue is recognized when all four of the following criteria are met: (i) a contract is executed; (ii) the contract price is fixed and determinable; (iii) delivery of the services or products has occurred; and (iv) collectability of the contract amounts is considered probable. Our collaborative research and development agreements provide for upfront license fees, research payments, and/or substantive milestone payments. Upfront non-refundable fees associated with license and development agreements where we have continuing involvement in the agreement are recorded as deferred revenue and recognized over the estimated service period. If the estimated service period is subsequently modified, the period over which the upfront fee is recognized is modified accordingly on a prospective basis. Upfront non-refundable license and development fees for which no future performance obligations exist are recognized when collection is assured. Substantive milestone payments are considered performance payments and are recognized upon achievement of the milestone if all of the following criteria are met: (i) achievement of the milestone involves a degree of risk and was not reasonably assured at the inception of the arrangement; (ii) substantive effort is involved in achieving the milestone; and (iii) the amount of the milestone payment is reasonable in relation to all of the deliverables and payment terms within the arrangement. Determination of whether a milestone meets the aforementioned conditions involves the judgment of management. Research and development revenue from cost-reimbursement and cost-plus fixed-fee agreements is recognized as earned based on the performance requirements of the contract. Revisions in revenues, cost, and billing factors, such as indirect rate estimates, are accounted for in the period of change. Reimbursable costs under such contracts are subject to audit and retroactive adjustment. Contract revenues and accounts receivable reported in the financial statements are recorded at the amount expected to be received. Contract revenues are adjusted to actual upon final audit and retroactive adjustment. Estimated contractual allowances are provided based on management’s evaluation of current contract terms and past experience with disallowed costs and reimbursement levels. Payments received in advance of work performed are recorded as deferred revenue. Research and development revenue from fixed-price best efforts arrangements is recognized as earned based on the performance requirements of the contract. Revenue under these arrangements is recognized when delivery to and acceptance by the customer has been received. During the period of performance, recoverable contract costs are accumulated on the balance sheet in other current assets, but no revenue or profit is recorded prior to customer acceptance of the contractually stated deliverables. Recoverable contract costs that are accumulated on the balance sheets include all direct costs associated with the arrangement and an allocation of indirect costs. Payments received in advance of customer acceptance are recorded as deferred revenue. Once customer acceptance has been received, revenue and recoverable contract costs are recognized. Over the course of the arrangement, we routinely evaluate whether revenue and profitability should be recognized in the current period. Any known or probable losses on projects are charged to operations in the period in which such losses are determined. Recent Accounting Pronouncements In November 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash”. This ASU clarifies the presentation requirements of restricted cash within the statement of cash flows. The changes in restricted cash and restricted cash equivalents during the period should be included in the beginning and ending cash and cash equivalents balance reconciliation on the statement of cash flows. When cash, cash equivalents, restricted cash, or restricted cash equivalents are presented in more than one line item within the statement of financial position, an entity shall calculate a total cash amount in a narrative or tabular format that agrees to the amount shown on the statement of cash flows. Details on the nature and amounts of restricted cash should also be disclosed. This standard is effective for annual and interim reporting periods for fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact this standard may have on our financial statements. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Clarification of Certain Cash Receipts and Cash Payments.” The objective of ASU 2016-15 is to eliminate the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows, by adding or clarifying guidance on eight specific cash flow issues. For public business entities, ASU 2016-15 is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted. ASU 2015-16 provides that the amendments in the update should be applied retrospectively to all periods presented, unless deemed impracticable, in which case, prospective application is permitted. The Company is currently evaluating the impact this standard may have on our financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842).” The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about their leasing arrangements. The amendments in this ASU are effective for annual and interim periods for fiscal years beginning after December 15, 2018. The adoption of this standard is expected to have a material impact on our financial position. The Company is currently evaluating the impact this standard may have on our results of operations. In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments — Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities,” which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The amendments in this ASU are effective for fiscal years and interim periods beginning after December 15, 2017, and are to be adopted by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company is currently evaluating the impact of adopting this standard. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606),” which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. ASU 2014-09 was originally going to be effective for us on January 1, 2017; however, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers (Topic 606) — Deferral of the Effective Date,” which deferred the effective date of ASU 2014-09 by one year to January 1, 2018. In March 2016, the FASB issued ASU No. 2016-8, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations.” The amendments in this ASU do not change the core principle of ASU No. 2014-09 but the amendments clarify the implementation guidance on reporting revenue gross versus net. The effective date for the amendments in this ASU is the same as the effective date of ASU No. 2014-09. In April 2016, the FASB issued ASU No. 2016-10, “Revenue from Contracts with Customers (Identifying Performance Obligations and Licensing),” to clarify the implementation guidance on identifying performance obligations and licensing. The standard allows for either “full retrospective” adoption, meaning the standard is applied to all of the periods presented, or “modified retrospective” adoption, meaning the standard is applied only to the most current period presented in the financial statements. The Company is currently evaluating the impact of adopting these standards. Nothing has come to the Company’s attention that would indicate the adoption of these standards will have a material impact on the Company’s financial statements. However, the adoption of these standards will have a material impact on the Company’s disclosures. There are no other applicable new accounting pronouncements issued but not effective until after March 31, 2017 that the Company believes could have a significant effect on our financial position or results of operations.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	(2) Fair Value Measurements For assets and liabilities measured at fair value, we utilize FASB Accounting Standards Codification (ASC) Section 820 “Fair Value Measurements and Disclosures” (ASC 820), which defines fair value and establishes a framework for fair value measurements. This standard establishes a three-level hierarchy for disclosure of fair value measurements. The hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels of inputs used to measure fair value are as follows: · Level 1 – Quoted prices in active markets for identical assets or liabilities; · Level 2 – Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and other inputs that are observable (e.g., interest rates, yield curves, volatilities and default rates, among others) or that can be corroborated by observable market data; and · Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, including certain pricing models, discounted cash flow methodologies, and similar techniques that use significant unobservable inputs. The following table presents information about assets and liabilities recorded at fair value on a recurring basis on the Condensed Balance Sheet at March 31, 2017: Quoted Prices in Active Markets for Significant Significant Total Carrying Identical Other Observable Unobservable Value on the Assets Inputs Inputs Balance Sheet (Level 1) (Level 2) (Level 3) (in thousands) Assets: Corporate bonds $ 1,749 $ - $ 1,749 $ - Total assets at fair value $ 1,749 $ - $ 1,749 $ - Liabilities: Warrant liabilities $ 2,034 $ - $ - $ 2,034 Total liabilities at fair value $ 2,034 $ - $ - $ 2,034 The following table presents information about assets and liabilities recorded at fair value on a recurring basis on the Condensed Balance Sheet at December 31, 2016: Quoted Prices in Active Markets for Significant Significant Total Carrying Identical Other Observable Unobservable Value on the Assets Inputs Inputs Balance Sheet (Level 1) (Level 2) (Level 3) (in thousands) Assets: Corporate notes and bonds $ 3,498 $ - $ 3,498 $ - Total assets at fair value $ 3,498 $ - $ 3,498 $ - Liabilities: Warrant liabilities $ 1,059 $ - $ - $ 1,059 Total liabilities at fair value $ 1,059 $ - $ - $ 1,059 We determine fair value for our investments in marketable securities with Level 1 inputs through quoted market prices and have classified them as available-for-sale. Our Level 2 investments consist of corporate notes and bonds maturing at various times in 2017. We review all investments for other-than-temporary impairment at least quarterly or as indicators of impairment exist. Indicators of impairment include the duration and severity of the decline in fair value as well as the intent and ability to hold the investment to allow for a recovery in the market value of the investment. In addition, we consider qualitative factors that include, but are not limited to, (i) the financial condition and business plans of the investee, including its future earnings potential, (ii) the investee’s credit rating and (iii) the current and expected market and industry conditions in which the investee operates. If a decline in the fair value of an investment is deemed by management to be other-than-temporary, we write down the cost basis of the investment to fair value, and the amount of the write down is included in net earnings. Such a determination is dependent on the facts and circumstances relating to each investment. We have determined there were no such impairments during the first quarter of 2017. During the first quarter of 2016, we determined that our equity security holding had incurred an other-than-temporary impairment as a result of the entity in which we held the equity being acquired by another company at a price lower than our carrying value. The stock of the entity is no longer being publicly traded. As a result of this impairment, we realized a loss of $4,000. All unrealized holding gains or losses related to our investments in marketable securities are reflected in accumulated other comprehensive loss in stockholders’ equity. The changes in accumulated other comprehensive loss were net unrealized gains of $2,000 and $5,000 for the three months ended March 31, 2017 and 2016, respectively.

Stock-Based Compensation Expens

Stock-Based Compensation Expense	3 Months Ended
	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation Expense	(3) Stock-Based Compensation Expense The following table summarizes stock-based compensation expense related to employee stock options for the three-month periods ended March 31, 2017 and March 31, 2016, which was allocated as follows: Three Months Ended March 31, 2017 2016 (in thousands) General and administrative $ 97 $ 136 Research and development 52 66 $ 149 $ 202 We use the Black-Scholes pricing model to value stock options. No stock options were granted in 2017. The estimated fair value of employee stock options granted during the three-month periods ended March 31, 2016 was calculated using the Black-Scholes model with the following weighted-average assumptions: For the Three Months Ended March 31, 2016 Risk-free interest rate 1.51 % Expected dividend yield 0.00 % Expected volatility 101.66 % Expected life (years) 6.46 Weighted-average fair value of options granted $ 0.46 The risk-free interest rate assumptions are based upon various U.S. Treasury rates as of the date of the grants. The dividend yield is based on the assumption that we do not expect to declare a dividend over the life of the options. The volatility assumptions are based on the weighted average volatility for the most recent one-year period as well as the volatility over the expected life of 6.46 years. The expected life of employee stock options represents the weighted average of combining the actual life of options that have already been exercised or cancelled with the expected life of all outstanding options. The expected life of outstanding options is calculated assuming the options will be exercised at the midpoint between the applicable vesting date and the full contractual term. The Company estimates forfeiture rates at the time of grant and revises these estimates, if necessary, in subsequent periods if actual forfeitures differ from the estimates. Forfeitures are estimated based on the demographics of current option holders and standard probabilities of employee turnover. The weighted-average fair value of the options granted for the three-month periods ended March 31, 2016 is $0.46. We do not record tax-related effects on stock-based compensation given our historical and anticipated operating experience and offsetting changes in our valuation allowance, which fully reserves against potential deferred tax assets. Stock Options The following table summarizes the stock option activity for the three-month period ended March 31, 2017: Weighted Weighted average average Aggregate Number exercise contractual intrinsic of shares price life (years) value (in thousands, except exercise price and contractual term data) Stock options outstanding, January 1, 2017 289 $ 30.95 Granted - - Expired (2 ) 261.00 Stock options outstanding at March 31, 2017 287 $ 29.50 6.70 $ 55 Vested or expected to vest at March 31, 2017 (a) 275 $ 30.27 6.62 $ 50 Exercisable at March 31, 2017 204 $ 35.81 5.95 $ 8 (a) This represents the number of vested options as of March 31, 2017, plus the number of unvested options as of March 31, 2017 that we expect to vest in the future based on our estimated forfeiture rate. Unrecognized stock-based compensation related to stock options was approximately $0.8 million as of March 31, 2017. This amount is expected to be expensed over a weighted average period of 1.9 years. There were no options exercised during the three-month periods ended March 31, 2017 or 2016. The following table summarizes information about our stock options outstanding and exercisable as of March 31, 2017: Outstanding Exercisable Weighted average Weighted Weighted remaining average average Range of exercise Number contractual exercise Number exercise prices of shares life (in years) price of shares price (number of shares in thousands) $0.00 - $7.00 70 8.97 $ 5.28 17 $ 5.60 $7.01 - $100.00 204 6.22 27.32 174 26.82 $100.01 - $200.00 5 1.02 171.39 5 171.39 $200.01 - $300.00 6 2.29 228.60 6 228.60 $300.01 - $410.00 2 0.05 410.00 2 410.00 287 6.70 $ 29.50 204 $ 35.81

Warrants

Warrants	3 Months Ended
	Mar. 31, 2017
Warrants [Abstract]
Warrants	(4) Warrants On May 10, 2016, in a registered offering pursuant to the 2014 shelf registration statement (as defined in Note 6 below), we sold 547,195 shares of our common stock (the “Shares”), at a purchase price of $9.1375 per share. In a private placement concurrent with the sale of the Shares, we sold to the investors who purchased the Shares warrants to purchase 410,396.8 shares of common stock (the “Warrants”). The Shares and the Warrants were sold pursuant to a securities purchase agreement for aggregate gross proceeds of $5.0 million. Subject to certain ownership limitations, the Warrants became exercisable on November 10, 2016 at an exercise price equal to $8.30 per share of common stock, subject to adjustments as provided under the terms of the Warrants. The Warrants are exercisable until November 10, 2022. In connection with the offering of the Shares and Warrants, we issued to the placement agent and its designees unregistered warrants to purchase an aggregate of 38,303.7 shares of our common stock (the “Placement Agent Warrants”). The Placement Agent Warrants have substantially the same terms as the Warrants, except that the Placement Agent Warrants will expire on May 4, 2021 and have an exercise price equal to $11.422 per share of common stock. A summary of the allocation of the proceeds of the offering is shown below: (in thousands) Allocated to warrant liabilities $ 2,511 Allocated to common stock and additonal paid-in capital 2,489 Total allocated gross proceeds $ 5,000 The closing costs of $699,861 included the 38,303.7 Placement Agent Warrants valued at $202,862, and $496,999 for placement agent and other fees. Based upon the estimated fair value of the Shares and Warrants in units, the Company allocated $250,279 to financing expense and $449,582 as stock issuance costs. The table below sets forth the Warrants and Placement Agent Warrants as of March 31, 2017: Offering Date Outstanding Warrants Exercise Price Expiration Date Status May 2016 410,396.8 $ 8.30 11/10/2022 Exercisable May 2016 38,303.7 11.4220 5/4/2021 Exercisable 448,700.5 The Warrants contain a provision for liquidated damages in the event that there is a failure to deliver shares of common stock within three days of receiving a notice to exercise. As a result of this liquidated damages provision, the Warrants require liability classification in accordance with ASC 480 and are recorded at fair value. The fair value of the Warrants has been determined under a Black-Scholes pricing model; assuming a weighted average 5.49 year remaining life for the warrants, 1.97% risk-free interest rate, a 104.24% expected volatility and no dividend yield, the weighted average fair value of warrant liability as of March 31, 2017 is $4.54. Changes in fair value are recorded against operations in the reporting period in which they occur; increases or decreases in fair value are recorded to other income/(expense) as a change in fair value of warrant liabilities.

Net Loss per Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Net Loss per Share	(5) Net Loss per Share Basic earnings per share is computed based upon the net loss available to common stock stockholders divided by the weighted average number of common stock shares outstanding during the period. The dilutive effect of common stock equivalents is included in the calculation of diluted earnings per share only when the effect of the inclusion would be dilutive. For the three-month periods ended March 31, 2017 and 2016 all common stock equivalent shares associated with our stock option plans and stock equivalent shares associated with our warrants were excluded from the denominator in the diluted loss per share calculation as their inclusion would have been antidilutive.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity	(6) Stockholders’ Equity On December 1, 2016, the Company effected a 1 for 10 reverse stock split of the Company’s outstanding stock. All share and per share amounts in the unaudited condensed financial statements and accompanying notes have been retroactively restated to reflect the split. On January 23, 2014, we filed a $75.0 million shelf registration statement on Form S-3 (the “2014 shelf registration statement”), with the SEC which was declared effective February 11, 2014 and allowed us to obtain financing through the issuance of any combination of common stock, preferred stock or warrants. Due to its expiration, the 2014 shelf registration statement is no longer available for use for primary offerings by the Company. On February 11, 2014, we entered into an Equity Distribution Agreement (the “EDA”) with Roth Capital Partners, LLC (“Roth Capital Partners”), pursuant to which we could sell from time to time up to $10.0 million of shares of our common stock, par value $0.001 per share, through Roth Capital Partners. Sales of shares pursuant to the EDA, if any, could be made by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act of 1933, as amended, including without limitation directly on the NASDAQ Capital Market, or any other existing trading market for the shares or through a market maker, or, if agreed by us and Roth Capital Partners, by any other method permitted by law, including but not limited to in negotiated transactions. Sales under the EDA were made pursuant to the 2014 shelf registration statement. As of March 31, 2014, we had sold 72,168 shares pursuant to the EDA for gross proceeds of approximately $2.6 million. We have not sold any shares under the EDA since that date, and we would not be able to do so until a new registration statement is filed pursuant to which sales under the EDA may be made. On March 18, 2014, we sold 287,000 shares of our common stock, par value $0.001, in a registered direct offering pursuant to the 2014 shelf registration statement (the “2014 RDO”), at a price of  $31.50 per share, resulting in gross proceeds of approximately $9.0 million. On May 10, 2016, in a registered offering pursuant to the 2014 shelf registration statement, we sold the Shares, as defined in Note 4 above, at a purchase price of  $9.1375 per share (together with the 2014 RDO, the “Registered Direct Offerings”). In a private placement concurrent with the sale of the Shares, we sold the Warrants to the investors who purchased the Shares. The Shares and Warrants, as defined in Note 4 above, were sold pursuant to a securities purchase agreement for aggregate gross proceeds of $5.0 million. Subject to certain ownership limitations, the Warrants became exercisable on November 10, 2016 at an exercise price equal to $8.30 per share of common stock, subject to adjustments as provided under the terms of the Warrants. The Warrants are exercisable until November 10, 2022. In connection with the offering of the Shares and Warrants, we issued to the placement agent and its designees unregistered warrants to purchase the Placement Agent Warrants, as defined in Note 4 above. The Placement Agent Warrants have substantially the same terms as the Warrants, except that the Placement Agent Warrants will expire on May 4, 2021 and have an exercise price equal to $11.422 per share of common stock. The net proceeds from the sale of the Shares and the Warrants are $4.5 million after deducting certain fees due to the placement agent and our estimated transaction expenses. As of March 31, 2017, pursuant to the EDA and the Registered Direct Offerings, we have sold 906,363 shares of our common stock since the 2014 shelf registration statement became effective on February 11, 2014, for gross proceeds of $16.6 million. These sales resulted in proceeds, net of issuance costs of approximately $15.1 million. The 2014 shelf registration statement expired on February 11, 2017. On February 24, 2016, we received notification from NASDAQ that the minimum bid price of our common stock had remained below $1.00 per share for 30 consecutive business days, and we therefore were not in compliance with the minimum bid price requirement for continued listing set forth in Marketplace Rule 5550(a)(2). The notification letter stated that we would be afforded 180 calendar days, or until August 22, 2016, to regain compliance with the minimum bid price requirement. On August 23, 2016, we received notification from NASDAQ that we had been afforded a second 180 calendar day grace period, or until February 21, 2017, to regain compliance. To regain compliance, the closing bid price of our common stock must have met or exceeded $1.00 per share for at least ten consecutive business days. NASDAQ may, in its discretion, require our common stock to maintain a bid price of at least $1.00 per share for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining we demonstrated an ability to maintain long-term compliance. On December 15, 2016, we received a notice from NASDAQ stating that the Company regained compliance with the $1.00 minimum bid price requirement for continued listing set forth in Marketplace Rule 5450(a)(1) because the closing bid price of the Company’s common stock met or exceeded $1.00 per share for at least 10 consecutive business days. The notice further stated that the NASDAQ matter relating to the Company’s non-compliance with the minimum bid price requirement, which the Company initially disclosed under Item 3.01 of its Current Report on Form 8-K filed with the Securities and Exchange Commission on February 26, 2016, is now closed. Effective September 7, 2011, we entered into a stockholder rights agreement (the “Stockholder Rights Agreement”) between the Company and American Stock Transfer & Trust Company, LLC, as rights agent. The Stockholder Rights Agreement was not adopted in response to any specific effort to acquire control of the Company. In connection with the adoption of the Stockholder Rights Agreement, the Company’s board of directors declared a dividend of one preferred stock purchase right (a “Right”) for each outstanding share of common stock to stockholders of record as of the close of business on September 7, 2011. Initially, the Rights will be represented by the Company’s common stock certificates or book entry notations, will not be traded separately from the common stock, and will not be exercisable. In the event that any person acquires beneficial ownership of 20% or more of the outstanding shares of the Company’s common stock, or upon the occurrence of certain other events, each holder of a Right, other than the acquirer, would be entitled to receive, upon payment of the purchase price, which is initially set at $32 per Right, a number of shares of GenVec common stock having a value equal to two times such purchase price. The Company’s board of directors is entitled to redeem the Rights at $0.001 per Right at any time before a person or group has acquired 20% or more of the Company’s common stock. The Rights will expire on September 7, 2021, subject to the Company’s right to extend such date, unless earlier redeemed or exchanged by the Company or terminated. The Rights will at no time have any voting rights. The Company has authorized 30,000 shares of Series B Junior Participating Preferred Stock in connection with the adoption of the Stockholder Rights Agreement. There was no Series B Junior Participating Preferred Stock issued or outstanding as of March 31, 2017. In connection with the execution of the Merger Agreement with Intrexon, we amended the Stockholder Rights Agreement to provide that none of Intrexon, Merger Sub or any of their respective associates or affiliates shall become an Acquiring Person under the Stockholder Rights Agreement and to otherwise exempt the Merger from triggering provisions or rights under the Stockholder Rights Agreement.

Collaborative Agreements

Collaborative Agreements	3 Months Ended
	Mar. 31, 2017
Collaborative Agreements [Abstract]
Collaborative Agreements	(7) Collaborative Agreements In January 2010, we entered into a research collaboration and license agreement with Novartis to discover and develop novel treatments for hearing loss and balance disorders. Under the terms of the agreement, we licensed the world-wide rights to our preclinical hearing loss and balance disorders program to Novartis. We received a $5.0 million upfront payment and Novartis purchased $2.0 million of our common stock. We were eligible, from the inception of the agreement, to receive up to an additional $206.6 million in milestone payments if certain clinical, regulatory, and sales milestones were met, including: up to $0.6 million for the achievement of preclinical development activities; up to $26.0 million for the achievement of clinical milestones (including non-rejection of an IND with respect to a covered product, the first patient visit in Phase I, Phase IIb and Phase III clinical trials); up to $45.0 million for the receipt of regulatory approvals; and up to $135.0 million for sales-based milestones. From September 2010 through October 2014, we achieved four milestones resulting in aggregate payments from Novartis of $5.6 million. We have not achieved any milestones since October 2014. The achieved milestones are as follows: Milestone Event Date Amount (1) Successful completion of certain preclinical development activities September 2010 $ 300,000 (2) Successful completion of certain preclinical development activities December 2011 300,000 (3) Non-rejection by the FDA of the IND filed by Novartis for CGF166 February 2014 2,000,000 (4) First patient treated in a Phase I clinical trial with CGF166 October 2014 3,000,000 As of April 30, 2017, milestones remaining available under the agreement included $21.0 million of additional clinical milestones, $45.0 million in regulatory milestones, and $135.0 million of sales-based milestones. Additionally, if a product is commercialized we are also entitled to tiered royalties on the annual net sales of licensed products, on a product-by-product and country-by-country basis, at percentage rates that range based on annual net sales from the mid-single digits to the low double digits until the earlier of (a) the expiration of the last valid claim with respect to applicable patent rights and (b) January 1 following a year in which annual net sales of the product declined by a specified percentage of the highest level of prior annual net sales where the decline is reasonably attributable in part to the marketing or sale of a competing product in the country. For the five years thereafter, in the applicable country we are entitled to tiered royalties of below 1% on annual net sales. The collaboration and license agreement is terminable for convenience upon notice by either party or for uncured material breach. In addition, the agreement allows us to receive funding from Novartis for a research program focused on developing additional adenovectors for hearing loss. During each of the three-month periods ended March 31, 2017 and 2016, we recognized $0.1 million for work performed under the agreement. In January 2016, we were notified by Novartis that enrollment was paused in the clinical study for CGF166. This pause was based on a review of data by the trial’s Data Safety Monitoring Board (the “DSMB”) in accordance with criteria in the trial protocol. On April 28, 2016, we were notified by Novartis, based on a review of safety and efficacy data from the nine patients currently enrolled in the study, that the DSMB recommended that the trial continue, subject to approval by the FDA. On July 25, 2016, we announced we were notified by Novartis, that the FDA had lifted the clinical hold on the trial. In February 2017, we were notified that the first patient in the fourth cohort of the trial had been dosed. In August 2010, we signed an agreement for the supply of services relating to development materials with Novartis, related to our collaboration in hearing loss and balance disorders. Under this agreement, valued at $14.9 million, we agreed to manufacture clinical trial material for up to two lead product candidates. During each of the three-month periods ended March 31, 2017 and 2016, we recognized $30,000 for services performed under this agreement. In March 2015, we announced a collaboration with TheraBiologics, Inc. to develop cancer therapeutics leveraging both our proprietary gene delivery platform and TheraBiologics’ proprietary neural stem cell technology. Depending on the manner of commercialization, we will be entitled to profit sharing and/or royalty and milestone payments for the products being developed under the collaboration. We will contribute technology, know-how, vector construction, and technical and regulatory support to the program, and TheraBiologics will be responsible for all other development costs. We anticipate TheraBiologics will advance a second generation neural stem cell-based cancer treatment utilizing our technology into the clinic by the first half of 2018. In April 2015, we announced a Research Collaboration Agreement with the LMIV under which we will build new vaccine candidates based on our proprietary adenovectors isolated from gorillas and designed to deliver novel antigens discovered at the LMIV. In June 2015, we announced a multi-faceted collaboration agreement with the School of Medicine at Washington University at St. Louis (“WUSTL”) under which we and WUSTL will create modified versions of our gorilla adenovectors that incorporate specialized targeting antibodies on the surface of the vectors. These antibodies are produced only by camels, alpacas and other camelids and are smaller and more stable in intracellular environments than their mouse or human counterparts. The ultimate goal of this collaboration is to create highly targeted therapeutics and vaccines. In December 2016, we entered into a n exclusive option agreement with Washington University in St. Louis to license intellectual property and technology related to gene editing and pulmonary endothelial cell targeting. If the option is exercised, the license will allow broad utilization of technology. The Company plans to initially focus on research utilizing the technology to develop treatments for hemophilia. Under the terms of the agreement In September 2016, we entered into a second amendment to our previously disclosed license agreement with Merial. Under the terms of the amendment we will provide Merial with certain biological materials and grant Merial the right to use the underlying GenVec technology to further develop and advance FMD vaccine product candidates.

Litigation

Litigation	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Litigation	(8) Litigation On March 28, 2017 and April 6, 2017, putative stockholder class actions were filed in the United States District Court for the District of Delaware styled, respectively, Parshall v. GenVec, Inc., et. al. Mussman v. GenVec, Inc., et al. Hoose v. GenVec, Inc. et al. Pillai v. GenVec, Inc. et al. Parshall Mussman Parshall Hoose Parshall Hoose On April 19, 2017, the plaintiffs in the Parshall Mussman Hoose Hoose Pillai On May 2, 2017, the parties to the Stockholder Actions entered into a Memorandum of Understanding (“MOU”) that calls for, among other things: (1) certain additional disclosures to be included in the proxy statement mailed to GenVec stockholders; (2) the withdrawal of the April 25 Letter in the Hoose Hoose Pillai Hoose Pilla Hoose Pillai

Reclassifications

Reclassifications	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reclassifications	(9) Reclassifications ​ On December 1, 2016, the Company effected a 1 for 10 reverse stock split of the Company’s outstanding stock. All share and per share amounts in the unaudited condensed financial statements and accompanying notes have been retroactively restated to reflect the split.

General (Policies)

General (Policies)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The (a) condensed balance sheet as of December 31, 2016, which has been derived from audited financial statements, and (b) unaudited interim condensed financial statements included herein have been prepared by GenVec, Inc. (“GenVec”, “we”, “our”, “us”, or the “Company”) without audit pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. We believe the disclosures are adequate to make the information presented not misleading. The condensed financial statements included herein should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to present fairly the financial position of the Company as of March 31, 2017 and December 31, 2016 and the results of its operations and cash flows for the three-month periods ended March 31, 2017 and March 31, 2016. The results of operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.
Business	Business GenVec is a clinical-stage biopharmaceutical company with an entrepreneurial focus on leveraging its proprietary AdenoVerse™ gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. We are pioneers in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. Our lead product candidate, CGF166, is licensed to Novartis Institutes for BioMedical Research, Inc. (together with Novartis AG and its subsidiary corporations, including Novartis Pharma AG, “Novartis”) and is currently in a Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. In addition to our internal and partnered pipeline, we also focus on opportunities to license our proprietary technology platform, including vectors and production cell lines, to potential collaborators in the biopharmaceutical industry for the development and manufacture of therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. We are working with prominent companies and organizations such as Novartis, Merial (a unit of Boehringer Ingelheim), Washington University in St. Louis, and the U.S. government, as well as promising young companies such as TheraBiologics, to support a portfolio of programs that addresses the prevention and treatment of a number of significant human and animal health concerns. Our combination of internal and partnered development programs address therapeutic areas such as hearing loss and balance disorders, oncology, bleeding disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (“RSV”), herpes simplex virus (“HSV”), malaria, and in the area of animal health, vaccines against foot-and-mouth disease (“FMD”). Our AdenoVerse gene delivery technology has the important advantage of localizing protein delivery in the body. This is accomplished by using our adenovector platform to locally deliver genes to cells, which then direct production of the desired protein. This approach reduces side effects typically associated with systemic delivery of proteins. For therapeutics, the goal is for the protein produced to have a meaningful effect in treating the cause, manifestation, or progression of the disease. For vaccines, the goal is to induce an immune response against a target protein or antigen. This is accomplished by using an adenovector to deliver a gene that causes production of an antigen, which then stimulates the desired immune reaction by the body. Our research and development activities yield product candidates that utilize our technology platform and represent potential commercial opportunities. For example, preclinical research in hearing loss and balance disorders indicates that the delivery of the atonal gene using our adenovector technology may have the potential to restore hearing and balance function. We are currently working with Novartis on the development of novel treatments for hearing loss and balance disorders that emerged from these research and development efforts. There are currently no effective therapeutic treatments available for patients who have lost all balance function, and hearing loss remains a major unmet medical problem. We have multiple vaccine candidates that leverage our core adenovector technology, including our vaccine candidates for the prevention or treatment of RSV and HSV. We also have a program to develop a vaccine for malaria, a program in which we are currently working in collaboration with the Laboratory of Malaria Immunology and Vaccinology (“LMIV”) of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (“NIAID”). Our business strategy is focused on entering into collaborative arrangements with third parties to complete the development and commercialization of our product candidates. In the event that third parties take over the development for one or more of our product candidates, the estimated completion date would largely be under the control of that third party rather than us. We cannot forecast with any degree of certainty which proprietary products or indications, if any, will be subject to future collaborative arrangements, in whole or in part, or how such arrangements would affect our development plan or capital requirements. Our programs may also benefit from subsidies, grants, or government or agency-sponsored studies that could reduce our development costs. An element of our business strategy is to pursue, as resources permit, the research and development of a range of product candidates for a variety of indications. This is intended to allow us to diversify the risks associated with our research and development expenditures. To the extent we are unable to maintain a broad range of product candidates, our dependence on the success of one or a few product candidates would increase. PLAN OF MERGER On January 24, 2017, the Company, Intrexon Corporation, a Virginia corporation (“Intrexon”), and Intrexon GV Holding, Inc., a Delaware corporation and wholly owned subsidiary of Intrexon (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, and on the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into GenVec (the “Merger”). GenVec will survive the Merger as a wholly owned subsidiary of Intrexon. For more information on the Merger, the Merger Agreement and its terms and conditions, see Note 11, “Subsequent Events,” . Except where it is clear from the context, the discussion in this Form 10-Q does not contemplate the consummation of the Merger or the integration of GenVec with Intrexon. GOING CONCERN As a result of the uncertainties involved in our business, we are unable to estimate the duration and completion costs of our research and development projects or when, if ever, and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete our research and development projects in a timely manner or our failure to enter into collaborative agreements, when appropriate, could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time to time in order to continue with our business strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business. Our estimated future capital requirements are uncertain and could change materially as a result of many factors, including the progress of our research, development, clinical, manufacturing, and commercialization activities. Management has determined the Company has suffered recurring losses from operations and has an accumulated deficit that raises substantial doubt about our ability to continue as a going concern for the next twelve months. The report of our independent registered public accounting firm for the year ended December 31, 2016 included an explanatory paragraph that expressed substantial doubt about our ability to continue as a going concern. Our financial statements do not include any adjustments that might result from the outcome of the uncertainty. If the merger with Intrexon is not consummated, our ability to continue as a going concern may depend on our ability to raise additional capital, attain further operating efficiencies, reduce expenditures, and, ultimately, to generate revenue. There are no assurances that these future funding and operating efforts will be successful. If management is unsuccessful in these efforts, our current capital is not expected to be sufficient to fund our operations for the next twelve months. Our financial statements as of March 31, 2017 do not include any adjustments that might result from the outcome of this uncertainty.
Use of Estimates	Use of Estimates The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, and revenues and expenses during the period. Critical accounting estimates involved in applying our accounting policies are those that require management to make assumptions about matters that are highly uncertain at the time the accounting estimate is made and those for which different estimates reasonably could have been used for the current period. Critical accounting estimates are also those which are reasonably likely to change from period to period, and would have a material impact on the presentation of our financial condition, changes in financial condition, or results of operations. Our most critical accounting estimates relate to accounting policies for strategic collaborations and research contract revenues, research and development activities, stock-based compensation, and warrant liabilities. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances. Actual results could differ from these estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts reported in the accompanying financial statements for cash, cash equivalents, investments, and warrant liabilities, approximate fair value of these financial instruments. The fair value for marketable securities and warrant liabilities is discussed in Notes 2 and 4, respectively.
Revenue Recognition	Revenue Recognition Revenue is recognized when all four of the following criteria are met: (i) a contract is executed; (ii) the contract price is fixed and determinable; (iii) delivery of the services or products has occurred; and (iv) collectability of the contract amounts is considered probable. Our collaborative research and development agreements provide for upfront license fees, research payments, and/or substantive milestone payments. Upfront non-refundable fees associated with license and development agreements where we have continuing involvement in the agreement are recorded as deferred revenue and recognized over the estimated service period. If the estimated service period is subsequently modified, the period over which the upfront fee is recognized is modified accordingly on a prospective basis. Upfront non-refundable license and development fees for which no future performance obligations exist are recognized when collection is assured. Substantive milestone payments are considered performance payments and are recognized upon achievement of the milestone if all of the following criteria are met: (i) achievement of the milestone involves a degree of risk and was not reasonably assured at the inception of the arrangement; (ii) substantive effort is involved in achieving the milestone; and (iii) the amount of the milestone payment is reasonable in relation to all of the deliverables and payment terms within the arrangement. Determination of whether a milestone meets the aforementioned conditions involves the judgment of management. Research and development revenue from cost-reimbursement and cost-plus fixed-fee agreements is recognized as earned based on the performance requirements of the contract. Revisions in revenues, cost, and billing factors, such as indirect rate estimates, are accounted for in the period of change. Reimbursable costs under such contracts are subject to audit and retroactive adjustment. Contract revenues and accounts receivable reported in the financial statements are recorded at the amount expected to be received. Contract revenues are adjusted to actual upon final audit and retroactive adjustment. Estimated contractual allowances are provided based on management’s evaluation of current contract terms and past experience with disallowed costs and reimbursement levels. Payments received in advance of work performed are recorded as deferred revenue. Research and development revenue from fixed-price best efforts arrangements is recognized as earned based on the performance requirements of the contract. Revenue under these arrangements is recognized when delivery to and acceptance by the customer has been received. During the period of performance, recoverable contract costs are accumulated on the balance sheet in other current assets, but no revenue or profit is recorded prior to customer acceptance of the contractually stated deliverables. Recoverable contract costs that are accumulated on the balance sheets include all direct costs associated with the arrangement and an allocation of indirect costs. Payments received in advance of customer acceptance are recorded as deferred revenue. Once customer acceptance has been received, revenue and recoverable contract costs are recognized. Over the course of the arrangement, we routinely evaluate whether revenue and profitability should be recognized in the current period. Any known or probable losses on projects are charged to operations in the period in which such losses are determined.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In November 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash”. This ASU clarifies the presentation requirements of restricted cash within the statement of cash flows. The changes in restricted cash and restricted cash equivalents during the period should be included in the beginning and ending cash and cash equivalents balance reconciliation on the statement of cash flows. When cash, cash equivalents, restricted cash, or restricted cash equivalents are presented in more than one line item within the statement of financial position, an entity shall calculate a total cash amount in a narrative or tabular format that agrees to the amount shown on the statement of cash flows. Details on the nature and amounts of restricted cash should also be disclosed. This standard is effective for annual and interim reporting periods for fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact this standard may have on our financial statements. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Clarification of Certain Cash Receipts and Cash Payments.” The objective of ASU 2016-15 is to eliminate the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows, by adding or clarifying guidance on eight specific cash flow issues. For public business entities, ASU 2016-15 is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted. ASU 2015-16 provides that the amendments in the update should be applied retrospectively to all periods presented, unless deemed impracticable, in which case, prospective application is permitted. The Company is currently evaluating the impact this standard may have on our financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842).” The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about their leasing arrangements. The amendments in this ASU are effective for annual and interim periods for fiscal years beginning after December 15, 2018. The adoption of this standard is expected to have a material impact on our financial position. The Company is currently evaluating the impact this standard may have on our results of operations. In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments — Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities,” which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The amendments in this ASU are effective for fiscal years and interim periods beginning after December 15, 2017, and are to be adopted by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company is currently evaluating the impact of adopting this standard. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606),” which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. ASU 2014-09 was originally going to be effective for us on January 1, 2017; however, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers (Topic 606) — Deferral of the Effective Date,” which deferred the effective date of ASU 2014-09 by one year to January 1, 2018. In March 2016, the FASB issued ASU No. 2016-8, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations.” The amendments in this ASU do not change the core principle of ASU No. 2014-09 but the amendments clarify the implementation guidance on reporting revenue gross versus net. The effective date for the amendments in this ASU is the same as the effective date of ASU No. 2014-09. In April 2016, the FASB issued ASU No. 2016-10, “Revenue from Contracts with Customers (Identifying Performance Obligations and Licensing),” to clarify the implementation guidance on identifying performance obligations and licensing. The standard allows for either “full retrospective” adoption, meaning the standard is applied to all of the periods presented, or “modified retrospective” adoption, meaning the standard is applied only to the most current period presented in the financial statements. The Company is currently evaluating the impact of adopting these standards. Nothing has come to the Company’s attention that would indicate the adoption of these standards will have a material impact on the Company’s financial statements. However, the adoption of these standards will have a material impact on the Company’s disclosures. There are no other applicable new accounting pronouncements issued but not effective until after March 31, 2017 that the Company believes could have a significant effect on our financial position or results of operations.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Schedule of assets and liabilities recorded at fair value on a recurring basis	The following table presents information about assets and liabilities recorded at fair value on a recurring basis on the Condensed Balance Sheet at March 31, 2017: Quoted Prices in Active Markets for Significant Significant Total Carrying Identical Other Observable Unobservable Value on the Assets Inputs Inputs Balance Sheet (Level 1) (Level 2) (Level 3) (in thousands) Assets: Corporate bonds $ 1,749 $ - $ 1,749 $ - Total assets at fair value $ 1,749 $ - $ 1,749 $ - Liabilities: Warrant liabilities $ 2,034 $ - $ - $ 2,034 Total liabilities at fair value $ 2,034 $ - $ - $ 2,034 The following table presents information about assets and liabilities recorded at fair value on a recurring basis on the Condensed Balance Sheet at December 31, 2016: Quoted Prices in Active Markets for Significant Significant Total Carrying Identical Other Observable Unobservable Value on the Assets Inputs Inputs Balance Sheet (Level 1) (Level 2) (Level 3) (in thousands) Assets: Corporate notes and bonds $ 3,498 $ - $ 3,498 $ - Total assets at fair value $ 3,498 $ - $ 3,498 $ - Liabilities: Warrant liabilities $ 1,059 $ - $ - $ 1,059 Total liabilities at fair value $ 1,059 $ - $ - $ 1,059

Stock-Based Compensation Expe17

Stock-Based Compensation Expense (Tables)	3 Months Ended
	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of stock-based compensation expense related to employee stock options	Three Months Ended March 31, 2017 2016 (in thousands) General and administrative $ 97 $ 136 Research and development 52 66 $ 149 $ 202
Schedule of weighted-average assumptions used in valuation of stock option	For the Three Months Ended March 31, 2016 Risk-free interest rate 1.51 % Expected dividend yield 0.00 % Expected volatility 101.66 % Expected life (years) 6.46 Weighted-average fair value of options granted $ 0.46
Schedule of stock option activity	Weighted Weighted average average Aggregate Number exercise contractual intrinsic of shares price life (years) value (in thousands, except exercise price and contractual term data) Stock options outstanding, January 1, 2017 289 $ 30.95 Granted - - Expired (2 ) 261.00 Stock options outstanding at March 31, 2017 287 $ 29.50 6.70 $ 55 Vested or expected to vest at March 31, 2017 (a) 275 $ 30.27 6.62 $ 50 Exercisable at March 31, 2017 204 $ 35.81 5.95 $ 8 (a) This represents the number of vested options as of March 31, 2017, plus the number of unvested options as of March 31, 2017 that we expect to vest in the future based on our estimated forfeiture rate.
Schedule of summary of stock options outstanding	Outstanding Exercisable Weighted average Weighted Weighted remaining average average Range of exercise Number contractual exercise Number exercise prices of shares life (in years) price of shares price (number of shares in thousands) $0.00 - $7.00 70 8.97 $ 5.28 17 $ 5.60 $7.01 - $100.00 204 6.22 27.32 174 26.82 $100.01 - $200.00 5 1.02 171.39 5 171.39 $200.01 - $300.00 6 2.29 228.60 6 228.60 $300.01 - $410.00 2 0.05 410.00 2 410.00 287 6.70 $ 29.50 204 $ 35.81

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2017
Warrants [Abstract]
Schedule of allocation of proceeds of the offering	(in thousands) Allocated to warrant liabilities $ 2,511 Allocated to common stock and additonal paid-in capital 2,489 Total allocated gross proceeds $ 5,000
Schedule of warrants and placement agent warrants	Offering Date Outstanding Warrants Exercise Price Expiration Date Status May 2016 410,396.8 $ 8.30 11/10/2022 Exercisable May 2016 38,303.7 11.4220 5/4/2021 Exercisable 448,700.5

Collaborative Agreements (Table

Collaborative Agreements (Tables)	3 Months Ended
	Mar. 31, 2017
Collaborative Agreements [Abstract]
Schedule of milestones achieved	Milestone Event Date Amount (1) Successful completion of certain preclinical development activities September 2010 $ 300,000 (2) Successful completion of certain preclinical development activities December 2011 300,000 (3) Non-rejection by the FDA of the IND filed by Novartis for CGF166 February 2014 2,000,000 (4) First patient treated in a Phase I clinical trial with CGF166 October 2014 3,000,000

Fair Value Measurements - Asset

Fair Value Measurements - Assets and liabilities recorded at fair value on recurring basis on condensed balance sheet (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)
Assets:
Total assets at fair value
Liabilities:
Total liabilities at fair value
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) | Warrant liabilities
Liabilities:
Total liabilities at fair value
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) | Corporate bonds
Assets:
Total assets at fair value
Significant Other Observable Inputs (Level 2)
Assets:
Total assets at fair value	1,749	3,498
Liabilities:
Total liabilities at fair value
Significant Other Observable Inputs (Level 2) | Warrant liabilities
Liabilities:
Total liabilities at fair value
Significant Other Observable Inputs (Level 2) | Corporate bonds
Assets:
Total assets at fair value	1,749	3,498
Significant Unobservable Inputs (Level 3)
Assets:
Total assets at fair value
Liabilities:
Total liabilities at fair value	2,034	1,059
Significant Unobservable Inputs (Level 3) | Warrant liabilities
Liabilities:
Total liabilities at fair value	2,034	1,059
Significant Unobservable Inputs (Level 3) | Corporate bonds
Assets:
Total assets at fair value
Total Carrying Value on the Balance Sheet
Assets:
Total assets at fair value	1,749	3,498
Liabilities:
Total liabilities at fair value	2,034	1,059
Total Carrying Value on the Balance Sheet | Warrant liabilities
Liabilities:
Total liabilities at fair value	2,034	1,059
Total Carrying Value on the Balance Sheet | Corporate bonds
Assets:
Total assets at fair value	$ 1,749	$ 3,498

Fair Value Measurements (Detail

Fair Value Measurements (Detail Textuals) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Fair Value Disclosure [Line Items]
Net unrealized gain included in comprehensive income related to marketable securities	$ 2,000	$ 5,000
Equity securities
Fair Value Disclosure [Line Items]
Accumulated unrealized loss	$ 4,000

Stock-Based Compensation Expe22

Stock-Based Compensation Expense - Summary of stock based compensation expense related to employee stock options (Details) - Employee stock options - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 149	$ 202
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	97	136
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 52	$ 66

Stock-Based Compensation Expe23

Stock-Based Compensation Expense - The estimated fair value of employee stock options granted (Details 1) - Employee stock options	3 Months Ended
	Mar. 31, 2016$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.51%
Expected dividend yield	0.00%
Expected volatility	101.66%
Expected life (years)	6 years 5 months 16 days
Weighted-average fair value of options granted	$ 0.46

Stock-Based Compensation Expe24

Stock-Based Compensation Expense - Stock option activity (Details 2) - Stock Options $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)$ / sharesshares
Number of shares
Stock options outstanding, January 1, 2017 | shares	289
Granted | shares
Expired | shares	(2)
Stock options outstanding at March 31, 2017 | shares	287
Vested or expected to vest at March 31, 2017 | shares	275	[1]
Exercisable at March 31, 2017 | shares	204
Weighted average exercise price
Stock options outstanding, January 1, 2017 | $ / shares	$ 30.95
Granted | $ / shares
Expired | $ / shares	261
Stock options outstanding at March 31, 2017 | $ / shares	29.50
Vested or expected to vest at March 31, 2017 | $ / shares	30.27	[1]
Exercisable at March 31, 2017 | $ / shares	$ 35.81
Weighted average contractual life (years)
Stock options outstanding, March 31, 2017	6 years 8 months 12 days
Vested or expected to vest at March 31, 2017	6 years 7 months 13 days	[1]
Exercisable at March 31, 2017	5 years 11 months 12 days
Aggregate intrinsic value
Stock options outstanding at March 31, 2017 | $	$ 55
Vested or expected to vest at March 31, 2017 | $	50	[1]
Exercisable at March 31, 2017 | $	$ 8
[1]	This represents the number of vested options as of March 31, 2017, plus the number of unvested options as of March 31, 2017 that we expect to vest in the future based on our estimated forfeiture rate.

Stock-Based Compensation Expe25

Stock-Based Compensation Expense - Summary of stock options outstanding (Details 3) - Stock Options - $ / shares	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, Number of shares	287	289
Outstanding, Weighted average remaining contractual life (in years)	6 years 8 months 12 days
Outstanding, Weighted average exercise price	$ 29.50	$ 30.95
Exercisable, Number of shares	204
Exercisable, Weighted average exercise price	$ 35.81
$0.00 - $7.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices, minimum	0
Range of exercise prices, maximum	$ 7
Outstanding, Number of shares	70
Outstanding, Weighted average remaining contractual life (in years)	8 years 11 months 19 days
Outstanding, Weighted average exercise price	$ 5.28
Exercisable, Number of shares	17
Exercisable, Weighted average exercise price	$ 5.60
$7.01 - $100.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices, minimum	7.01
Range of exercise prices, maximum	$ 100
Outstanding, Number of shares	204
Outstanding, Weighted average remaining contractual life (in years)	6 years 2 months 19 days
Outstanding, Weighted average exercise price	$ 27.32
Exercisable, Number of shares	174
Exercisable, Weighted average exercise price	$ 26.82
$100.01 - $200.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices, minimum	100.01
Range of exercise prices, maximum	$ 200
Outstanding, Number of shares	5
Outstanding, Weighted average remaining contractual life (in years)	1 year 7 days
Outstanding, Weighted average exercise price	$ 171.39
Exercisable, Number of shares	5
Exercisable, Weighted average exercise price	$ 171.39
$200.01 - $300.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices, minimum	200.01
Range of exercise prices, maximum	$ 300
Outstanding, Number of shares	6
Outstanding, Weighted average remaining contractual life (in years)	2 years 3 months 15 days
Outstanding, Weighted average exercise price	$ 228.60
Exercisable, Number of shares	6
Exercisable, Weighted average exercise price	$ 228.60
$300.01 - $410.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices, minimum	300.01
Range of exercise prices, maximum	$ 410
Outstanding, Number of shares	2
Outstanding, Weighted average remaining contractual life (in years)	18 days
Outstanding, Weighted average exercise price	$ 410
Exercisable, Number of shares	2
Exercisable, Weighted average exercise price	$ 410

Stock-Based Compensation Expe26

Stock-Based Compensation Expense (Detail Textuals) - Stock Options - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Stockholders Equity [Line Items]
Expected life (years)		6 years 5 months 16 days
Weighted-average fair value of options granted		$ 0.46
Unrecognized stock-based compensation expense	$ 0.8
Unrecognized stock-based compensation, weighted average recognition period	1 year 10 months 24 days

Warrants - Summary of allocatio

Warrants - Summary of allocation of offering (Details) - USD ($) $ in Thousands	May 10, 2016	Mar. 31, 2017
Warrants [Abstract]
Allocated to warrant liabilities		$ 2,511
Allocated to common stock and additional paid-in capital		2,489
Total allocated gross proceeds	$ 4,500	$ 5,000

Warrants - Summary of warrants

Warrants - Summary of warrants and Placement Agent Warrants (Details 1)	3 Months Ended
	Mar. 31, 2017$ / sharesshares
8.30
Class of Warrant or Right [Line Items]
Warrants Offering Date	2016-05
Class of Warrant or Right, Outstanding | shares	410,396.8
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 8.30
Warrant Expiration Date	Nov. 10, 2022
Status Of Warrants	Exercisable
11.4220
Class of Warrant or Right [Line Items]
Warrants Offering Date	2016-05
Class of Warrant or Right, Outstanding | shares	38,303.7
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 11.4220
Warrant Expiration Date	May 4, 2021
Status Of Warrants	Exercisable

Warrants (Detail Textuals)

Warrants (Detail Textuals) - USD ($) $ / shares in Units, $ in Thousands	May 10, 2016	Mar. 31, 2017
Class of Warrant or Right [Line Items]
Number of shares of common stock sold	547,195
Purchase price of shares	$ 9.1375
Proceeds of sale of shares and warrants	$ 4,500	$ 5,000
Warrant
Class of Warrant or Right [Line Items]
Closing costs of the financing		699,861
Value of warrants		202,862
Placement agent and other fees		496,999
Financing expense		250,279
Stock issuance costs		$ 449,582
Fair value of warrants, valuation techniques		Black-Scholes pricing model
Weighted average remaining life of warrants		5 years 5 months 27 days
Risk-free interest		1.97%
Expected volatility		104.24%
Weighted average fair value of warrant liability		$ 4.54
Warrant | Investor
Class of Warrant or Right [Line Items]
Number of warrants to purchase shares of common stock	410,396.8
Proceeds of sale of shares and warrants	$ 5,000
Warrant exercise price	$ 8.30
Placement Agent Warrants
Class of Warrant or Right [Line Items]
Number of warrants to purchase shares of common stock	38,303.7
Warrant exercise price	$ 11.422

Stockholders' Equity (Detail Te

Stockholders' Equity (Detail Textuals) - USD ($) $ / shares in Units, $ in Thousands	Dec. 01, 2016	May 10, 2016	Feb. 11, 2014	Mar. 31, 2014	Mar. 18, 2014	Mar. 31, 2017	Dec. 31, 2016	Jan. 23, 2014
Class of Warrant or Right [Line Items]
Reverse stock split	1 for 10
Stock issuance maximum limit								$ 75,000
Proceeds from issuance or sale of equity		$ 4,500				$ 5,000
Common stock, par value (in dollars per share)						$ 0.001	$ 0.001
Number of shares sold under registered direct offering		547,195
Offering price		$ 9.1375
Registered Direct Offering
Class of Warrant or Right [Line Items]
Proceeds from issuance or sale of equity						$ 16,600
Common stock, par value (in dollars per share)					$ 0.001
Number of shares sold						906,363
Number of shares sold under registered direct offering					287,000
Offering price					$ 31.50
Value of shares sold under registered direct offering					$ 9,000
Proceeds of shares sold net of issuance cost						$ 15,100
Roth Equity Distribution Agreement | ATM offering
Class of Warrant or Right [Line Items]
Proceeds from issuance or sale of equity			$ 10,000	$ 2,600
Common stock, par value (in dollars per share)			$ 0.001
Number of shares sold				72,168
Warrant | Investor
Class of Warrant or Right [Line Items]
Proceeds from issuance or sale of equity		$ 5,000
Number of warrants to purchase shares of common stock		410,396.8
Warrant exercise price		$ 0.83
Placement Agent Warrants
Class of Warrant or Right [Line Items]
Number of warrants to purchase shares of common stock		38,303.7
Warrant exercise price		$ 11.422

Stockholders' Equity (Detail 31

Stockholders' Equity (Detail Textuals 2)	Dec. 15, 2016Day$ / shares	Sep. 07, 2011$ / sharesshares	Aug. 23, 2016Day$ / shares	Feb. 24, 2016Day$ / shares	Mar. 31, 2017shares	Dec. 31, 2016shares
Class of Stock [Line Items]
Minimum bid price	$ 1		$ 1	$ 1
Closing bid price	$ 1		$ 1	$ 1
Consecutive trading days			10 days	20 days
Consecutive business days | Day	10		20	30
Preferred stock, shares authorized | shares					5,000,000	5,000,000
Series B Junior Participating Preferred Stock | Stockholder Rights Agreement | American Stock Transfer And Trust Company Llc
Class of Stock [Line Items]
Common stock ownership		20.00%
Purchase price		$ 32
Preferred stock, shares authorized | shares		30,000
Redeem right per share		$ 0.001

Collaborative Agreements (Detai

Collaborative Agreements (Details)	3 Months Ended
	Mar. 31, 2017USD ($)
Successful completion of certain preclinical development activities | September 2010
Collaborative Arrangements and Non-Collaborative Arrangement Transactions [Line Items]
Milestone method, revenue recognized	$ 300,000
Successful completion of certain preclinical development activities | December 2011
Collaborative Arrangements and Non-Collaborative Arrangement Transactions [Line Items]
Milestone method, revenue recognized	300,000
Non-rejection by the FDA of the IND filed by Novartis for CGF166 | February 2014
Collaborative Arrangements and Non-Collaborative Arrangement Transactions [Line Items]
Milestone method, revenue recognized	2,000,000
First patient treated in a Phase I clinical trial with CGF166 | October 2014
Collaborative Arrangements and Non-Collaborative Arrangement Transactions [Line Items]
Milestone method, revenue recognized	$ 3,000,000

Collaborative Agreements (Det33

Collaborative Agreements (Detail Textuals)	1 Months Ended		3 Months Ended		12 Months Ended
	Aug. 31, 2010USD ($)Candidate	Jan. 31, 2010USD ($)	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2016USD ($)	Apr. 30, 2017USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement expected service revenue			$ 206,600,000
Collaboration and License Agreement | Preclinical Development Activities
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement expected service revenue			600,000
Collaboration and License Agreement | Clinical Milestone Events
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement expected service revenue			26,000,000
Collaboration and License Agreement | Regulatory Approvals
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement expected service revenue			45,000,000
Collaboration and License Agreement | Sales Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement expected service revenue			135,000,000
Collaboration and License Agreement | Novartis
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone method, revenue recognized			5,600,000
Upfront Payment		$ 5,000,000
Value of common stock purchased		$ 2,000,000
Value of work performed under agreement			100,000	$ 100,000
Service Agreements | Novartis
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Service revenue net	$ 14,900,000
Number of lead product candidate | Candidate	2
Value of work performed under agreement			$ 30,000	$ 30,000
Service Agreements | Novartis | Clinical Milestone Events | Subsequent event
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement expected service revenue						$ 21,000,000
Service Agreements | Novartis | Regulatory Approvals | Subsequent event
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement expected service revenue						45,000,000
Service Agreements | Novartis | Sales Milestones | Subsequent event
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement expected service revenue						$ 135,000,000
Washington university agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Amount agreed to be payable under agreement					$ 300,000
Term of agreement					2 years

Reclassifications (Detail Textu

Reclassifications (Detail Textuals)	Dec. 01, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reverse stock split	1 for 10